Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index; 25 of the 125 sources its claims cite were checked for support.

Gut microbiota-mediated immunomodulation in tumor

Open access
Liu, Xinyi, Chen, Yanjie, Zhang, Si, Dong, Ling · 2021 · Journal of Experimental & Clinical Cancer Research

Abstract

Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In addition to pathogen defense and maintaining the intestinal ecosystem, gut microbiota also plays a pivotal role in various physiological processes. Recently, the association between these symbionts and cancer, ranging from oncogenesis and cancer progression to resistance or sensitivity to antitumor therapies, has attracted much attention. Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals. Moreover, modulation of microbiome could improve therapeutic response to immune checkpoint inhibitors (ICIs). These findings suggest that microbiome is involved in cancer pathogenesis and progression through regulation of tumor immunosurveillance, although the exact mechanisms remain largely unknown. This review focuses on the interaction between the microbiome and tumor immunity, with in-depth discussion regarding the therapeutic potential of modulating gut microbiota in ICIs. Further investigations are warranted before gut microbiota can be introduced into clinical practice.

Overview

CoChat Summary

TL;DR

This review synthesizes evidence that gut microbiota shapes antitumor immunity through innate and adaptive immune cells, microbial PAMPs, metabolites, and secondary lymphoid organ effects. It argues that microbiota modulation may improve immune checkpoint inhibitor (ICI) efficacy, but mechanisms remain unclear and clinical translation requires more rigorous trials.

Key findings

  • Cancer patients show altered gut microbial composition versus healthy individuals; for example, colorectal cancer patients have decreased microbial diversity and increased carriage of *Fusobacterium nucleatum*, which is associated with regional lymph node metastasis and shorter survival, while hepatocellular carcinoma patients show increased *Bacteroides* and Ruminococcaceae and lower *Bifidobacterium*.
  • Microbiota can promote or suppress tumor immunity: dysbiosis can induce M2-like tumor-associated macrophages, MDSCs, and reduced cytotoxic NK cells, whereas favorable taxa such as *Bifidobacterium*, *Bacteroides fragilis*, and Ruminococcaceae enhance DC activation, CD8+ T cell responses, and IFN-γ production.
  • Proposed mechanisms include PAMP–TLR/NF-κB signaling (e.g., LPS, LTA, flagellin), microbiota-derived metabolites such as SCFAs and bile acids, and bacterial translocation affecting secondary lymphoid organs.
  • In ICI studies, responders are often enriched for taxa including Ruminococcaceae, *Faecalibacterium*, and *Akkermansia muciniphila*; antibiotics are frequently associated with shorter PFS/OS, including meta-analyses of 2740 and 5565 cancer patients, and responder-derived FMT reversed anti-PD-1 resistance in 6 of 15 patients in one study and produced responses in 3 of 10 refractory melanoma patients in another.

Methods

  • Narrative review of preclinical and clinical literature on gut microbiota–tumor immunity interactions and microbiota modulation in ICI therapy.
  • No primary data are reported; the paper synthesizes cited mouse, in vitro, and human studies and includes three tables: microbial profiles associated with ICI response, antibiotics use and ICI efficacy, and ongoing clinical trials of microbiome interventions.
  • Main analysis is qualitative synthesis rather than systematic review or meta-analysis.

Limitations

  • Stated: exact mechanisms remain largely unknown; most studies were done in mice or in vitro; clinical situations are complicated by tumor type/stage, prior treatments, and host factors; immunocyte phenotypes/functions are heterogeneous; the microbiome–cancer relationship is likely bidirectional.
  • Stated for antibiotics studies: mostly retrospective without intervention, variable antibiotic class/dose/duration, possible recovery of microbiome before ICI, confounding by infection/inflammation, non-microbiome effects of antibiotics, and small sample sizes.
  • Evident: as a narrative review, it lacks a systematic search strategy, formal inclusion criteria, and risk-of-bias assessment; low concordance across microbiota studies is noted and attributed to differing techniques and unadjusted host variables.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13046-021-01983-x

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Tumor Immunosurveillance. Tumor immunosurveillance can be divided into two parts, namely innate immunity and adaptive immunity. The former involves various types of myeloid lineage cells and innate lymphoid cells (ILCs), such as macrophage and NK cell. NK cells can kill tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC), FAS-FASL pathways and perforin-granzyme B. In addition to ADCC and opsonization, macrophages also act as antigen-presenting cells (APC). Adaptive immunity begins with tumor antigen recognized by T cell receptor (TCR), during which dendritic cells (DCs) play a dominant role. Neoantigens generated during oncogenesis are released and captured by DCs for processing. DCs present antigen peptide to T cells in the form of peptide-MHC complex (pMHC). TCR-pMHC interaction combined with costimulatory signal results in the priming of effector T cells. Then the activated T cells, which can specifically target the cancer cells, migrate to the tumor bed and kill the cancer cells through direct cytotoxic effect or producing cytokines to recruit more immune cells
Fig. 1 Tumor Immunosurveillance. Tumor immunosurveillance can be divided into two parts, namely innate immunity and adaptive immunity. The former involves various types of myeloid lineage cells and innate lymphoid cells (ILCs), such as macrophage and NK cell. NK cells can kill tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC), FAS-FASL pathways and perforin-granzyme B. In addition to ADCC and opsonization, macrophages also act as antigen-presenting cells (APC). Adaptive immunity begins with tumor antigen recognized by T cell receptor (TCR), during which dendritic cells (DCs) play a dominant role. Neoantigens generated during oncogenesis are released and captured by DCs for processing. DCs present antigen peptide to T cells in the form of peptide-MHC complex (pMHC). TCR-pMHC interaction combined with costimulatory signal results in the priming of effector T cells. Then the activated T cells, which can specifically target the cancer cells, migrate to the tumor bed and kill the cancer cells through direct cytotoxic effect or producing cytokines to recruit more immune cellsCC BY · PubMed Central
Fig. 2 Potential Mechanisms for Microbiota-Mediated Immunomodulation in Tumor (see attached file). Gut microflora can exert an impact on tumor immunity both locally and systemically. Locally, Fusobacterium may act on CRC cells via TLR4/MYD88 signaling pathway. The activation of NF-kB promoted the transcription of pro-inflammatory cytokines such as TNF-α and IL-6, leading to the accumulation of immunosuppressive myeloid cells in TME. Systemically, bacterial flagellin accelerated distal malignant progression via TLR5 signaling, resulting in increased systemic IL-6 and subsequent more γδT cells to produce immunosuppressive galectin-1. Furthermore, the enterohepatic circulation enabled microbiota-derived PAMP and metabolites to play a role in HCC. On one hand, in the context of HCC, there is a significant increase in portal and systemic LPS, owing to dysbiosis and increased gut permeability. Elevated LPS activated NF-κB in HSC, inducing production of inflammatory chemokines. These cytokines could enhance migration of macrophages and MDSCs to the liver. Similarly, gut-derived LTA induced the expression of COX2 to promote local production of PGE2. Then PGE2 suppressed the antitumor response through the PTGER4 receptor on immune cells, manifested as decreased production of IFN-γ and TNF-α, reduced CD103+DC and increased CD4+FOXP3+Treg. On the other hand, depletion of gram-positive bacteria involved in primary-to-secondary bile acid conversion increased the expression of CXCL16. Upregulation of CXCL16 induced accumulation and activation of CXCR6+NKT cells, which suppressed liver tumor growth. In addition, intestinal microbiota could also control the immune tone of secondary lymphoid organs via bacterial translocation. The translocation of selected Gram-positive bacterial species into spleen is indispensable for CTX-driven accumulation of pTh17 cells, which increased systemic CD8+T cells and intratumoral CTL/Treg ratio. BA: bile acid; CRC: colorectal cancer; TLR: Toll-like receptor; TME: tumor microenvironment; PAMP: pathogen-associated molecule pattern; HCC: hepatocellular carcinoma; LPS: lipopolysaccharide; MDSC: myeloid-derived suppressor cells; LTA: lipoteichoic acid; HSC: hepatic stellate cell; HSEC: hepatic sinusoidal endothelial cell; SCFA: short-chain fatty acids
Fig. 2 Potential Mechanisms for Microbiota-Mediated Immunomodulation in Tumor (see attached file). Gut microflora can exert an impact on tumor immunity both locally and systemically. Locally, Fusobacterium may act on CRC cells via TLR4/MYD88 signaling pathway. The activation of NF-kB promoted the transcription of pro-inflammatory cytokines such as TNF-α and IL-6, leading to the accumulation of immunosuppressive myeloid cells in TME. Systemically, bacterial flagellin accelerated distal malignant progression via TLR5 signaling, resulting in increased systemic IL-6 and subsequent more γδT cells to produce immunosuppressive galectin-1. Furthermore, the enterohepatic circulation enabled microbiota-derived PAMP and metabolites to play a role in HCC. On one hand, in the context of HCC, there is a significant increase in portal and systemic LPS, owing to dysbiosis and increased gut permeability. Elevated LPS activated NF-κB in HSC, inducing production of inflammatory chemokines. These cytokines could enhance migration of macrophages and MDSCs to the liver. Similarly, gut-derived LTA induced the expression of COX2 to promote local production of PGE2. Then PGE2 suppressed the antitumor response through the PTGER4 receptor on immune cells, manifested as decreased production of IFN-γ and TNF-α, reduced CD103+DC and increased CD4+FOXP3+Treg. On the other hand, depletion of gram-positive bacteria involved in primary-to-secondary bile acid conversion increased the expression of CXCL16. Upregulation of CXCL16 induced accumulation and activation of CXCR6+NKT cells, which suppressed liver tumor growth. In addition, intestinal microbiota could also control the immune tone of secondary lymphoid organs via bacterial translocation. The translocation of selected Gram-positive bacterial species into spleen is indispensable for CTX-driven accumulation of pTh17 cells, which increased systemic CD8+T cells and intratumoral CTL/Treg ratio. BA: bile acid; CRC: colorectal cancer; TLR: Toll-like receptor; TME: tumor microenvironment; PAMP: pathogen-associated molecule pattern; HCC: hepatocellular carcinoma; LPS: lipopolysaccharide; MDSC: myeloid-derived suppressor cells; LTA: lipoteichoic acid; HSC: hepatic stellate cell; HSEC: hepatic sinusoidal endothelial cell; SCFA: short-chain fatty acidsCC BY · PubMed Central

Verification

Claims the paper makes

20 Valid · 1 Not valid · 81 Not checked · 16 Own results and interpretations

62 more claims · 11 with their cited sources checked

Create a free account to see all 118 claims and to verify the 100 references still open.

See all claims — free account
  • It may state two separate claims as one. 49
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

1 retracted

Show all 139 references

Cited by

See all 112

Metadata

Authors
Liu, X., Chen, Y., Zhang, S., & Dong, L.
Affiliations
Shanghai Medical College of Fudan University (CN)
Corresponding author
  • Zhang, Si
  • Dong, Ling
Venue
Journal of Experimental & Clinical Cancer Research
Published
2021-07-03
Volume
40
Issue
1
Pages
221-221
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W3181453493
Cited by
112
References
139
Citations by year
2026: 25 · 2025: 27 · 2024: 22 · 2023: 20 · 2022: 16 · 2021: 1
FWCI
1.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81900482)
  • Zhongshan Hospital (2018ZSLC09)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
gut microbiota, antitumor immunity, immunomodulation, immune checkpoint inhibitors, microbiota modulation, tumor surveillance, tumor progression, carcinogenesis, metagenomics, cancer patients
MeSH terms
Gastrointestinal Microbiome, Humans, Neoplasms, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut microbiota-mediated immunomodulation in tumor. https://app.cochat.ai/papers/10.1186/s13046-021-01983-x
The paper
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021). Gut microbiota-mediated immunomodulation in tumor. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-021-01983-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.